慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义*

doi:10.3969/j.issn.1672-5069.2019.06.012

摘要/Abstract

摘要： 目的研究慢性乙型肝炎（CHB）患者血清脂肪细胞因子水平及其临床意义。方法 2014年11月~2018年4月我院收治的154例CHB患者和同期来我院体检的健康人154例,采用ELISA法检测血清内脏脂肪素、瘦素、脂联素和网膜素水平。所有患者接受肝活检,将肝组织炎症活动度评分为G3或G4者,判定为肝组织严重炎症活动,将肝纤维化S3期和S4期视为严重肝纤维化或肝硬化。结果 CHB患者血清内脏脂肪素、瘦素和脂联素水平健康人比较,差异无统计学意义（P>0.05）,而CHB患者血清网膜素水平为（361.0±132.4） μg/L,显著高于健康人的（300.9±110.5） μg/L（P<0.05）;89例肝组织严重炎症活动与65例轻度炎症活动患者血清内脏脂肪素、瘦素、脂联素和网膜素水平比较差异无统计学意义（P>0.05）;96例肝组织严重纤维化患者与58例轻度纤维化患者血清内脏脂肪素、瘦素和脂联素水平比较差异无统计学意义（P>0.05）,而肝组织严重纤维化患者血清网膜素水平为（397.8±150.4） μg/L,显著高于肝组织轻度纤维化患者的（316.7±118.5） μg/L（P<0.05）。结论 CHB患者血清网膜素水平显著升高,且肝组织严重纤维化患者血清网膜素水平显著升高,或许可以用来帮助评估肝内病变。

关键词: 慢性乙型肝炎, 脂肪细胞因子, 肝纤维化, 肝组织炎症

Abstract: Objective The aim of this study was to investigate the implications of serum adipocytokines in patients with chronic hepatitis B（CHB）. Methods 154 patients with CHB and 154 healthy persons were recruited in our hospital between November 2014 and April 2018,and serum visfatin,leptin,adiponectin and omentin levels were detected by ELISA. All patients with CHB received liver biopsies. Results There were no significant differences as respect to serum visfatin,leptin,and adiponectin levels in patients with CHB and in healthy persons（P>0.05）,while serum omentin level in patients with CHB was（361.0±132.4） μg/L,significantly higher than （300.9±110.5） μg/L（P﹤0.05）;there were no significant differences as respect to serum visfatin,leptin,adiponectin and omentin levels in 89 patients with severe and in 65 with mild intrahepatic histological activities（P>0.05）;there were also no significant differences as respect to serum visfatin,leptin,and adiponectin in 96 patients with severe and in 58 with mild liver fibrosis（P>0.05）,while serum omentin level in patients with severe liver fibrosis was （397.8±150.4） μg/L,significantly higher than （316.7±118.5） μg/L（P﹤0.05） in patients with mild liver fibrosis. Conclusion Serum omentin levels in patients with CHB increase greatly,and might be related to the severity of liver fibrosis,which might help predict the intrahepatic liver tissue lesions in clinical practice.

Key words: Hepatitis B, Hepatic fibrosis, Adipocytokines, Liver histopathology

闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.

Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.

参考文献

[1] Tsochatzis EA,Bosch J,Burroughs AK.Liver cirrhosis. Lancet,2014,383(9930):1749-1761.
[2] Dai CY,Yeh ML,Huang CF,et al.Chronic hepatitis C infection is associated with insulin resistance and lipid profiles. J Gastroenterol Hepatol,2015,30(5):879-884.
[3] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[4] Huang Y,Deng X,Liang J.Modulation of hepatic stellate cells and reversibility of hepatic fibrosis. Exp Cell Res,2017,352(2):420-426.
[5] Iacono OL,Venezia G,Petta S,et al.The impact of insulin resistance,serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther,2010,25(10):1181-1191.
[6] 潘莉,韩真. 脂肪细胞因子在非酒精性脂肪肝发病机制中的作用. 实用肝脏病杂志,2010,13(2):151-154.
[7] Li BA,Liu J,Hou J,et al.Autoantibodies in Chinese patients with chronic hepatitis B:prevalence and clinical associations. World J Gastroenterol,2015,21(1):283-291.
[8] Mohamadnejad M,Tavangar SM,Kosari F,et al. S2068 histopath-ological study of chronic hepatitis B:A comparative study of Ishak and Metavir scoring systems. Int J Organ Transplant Med,2010,1(4):A-308-A-308.
[9] Komatsu H,Inui A,Fujisawa T,et al.Transmission route and genotype of chronic hepatitis B virus infection in children in Japan between 1976 and 2010:A retrospective,multicenter study. Hepatol Res,2015,45(6):629-637.
[10] Zhang C,Zhong Y,Guo L.Strategies to prevent hepatitis B virus infection in China:immunization,screening,and standard medical practices. Biosci Trends,2013,7(1):7-12.
[11] Terrault NA,Lok AS,Mcmahon BJ,et al.Update on prevention,diagnosis,and treatment and of chronic hepatitis B:AASLD 2018 Hepatitis B Guidance. Hepatology,2018,67(4):1560-1599.
[12] de Lédinghen V,Vergniol J. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices,2014,7(6):811-823.
[13] Fernandes FF,Perazzo H,Andrade LE,et al.Latent class analysis of noninvasive methods and liver biopsy in chronic hepatitis C:An approach without a gold standard. Biomed Res Int,2017,2017(3):1-8.
[14] Patel K,Bedossa P,Castera L.Diagnosis of liver fibrosis:Present and future. Semin Liver Dis,2015,35(2):166-183.
[15] 陆水英. 瘦素和网膜素在妇产科领域研究进展. 中华实用诊断与治疗杂志,2014,28(3):215-217.
[16] Yamawaki H.Vascular effects of novel adipocytokines:Focus on vascular contractility and inflammatory responses. Biol Pharm Bull,2011,34(3):307-310.
[17] Smith CCT,Yellon DM.Adipocytokines,cardiovascular pathophysiology and myocardial protection. Pharmacol Ther,2011,129(2):206-219.
[18] 林介军,周建伟,朱方超,等. 脂肪细胞因子与肝纤维化乙型肝炎患者肝功能、纤维化及炎症活动程度的相关性研究. 浙江医学,2017,39(16):1341-1344.
[19] Farzaneh M,Alireza B,Mansour K,et al.Serum omentin-1,vaspin,and apelin levels and central obesity in patients with nonalcoholic fatty liver disease. J Res Med Sci,2017,22(1):70.
[20] Eisinger K,Krautbauer S,Wiest R,et al.Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur J Clin Invest,2013,43(9):926-932.
[21] Zhang XY,Yuan Y,Zhou LY,et al.Omentin-1,a new adipokine,promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol,2013,698(1-3):137-144.

慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*

Implications of serum adipocytokine levels in patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[2]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[3]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[6]	汪道伟, 方坚, 范凌. 自身免疫性肝炎患者血清IL-21和趋化因子水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 844-847.
[7]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[8]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[9]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[10]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[11]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[12]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[15]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.